Skinfold thickness for rivastigmine patch application in Alzheimer’s disease
Rivastigmine patches are used for patients with Alzheimer’s disease (AD), but little is known about the serum concentration of rivastigmine and its metabolite or clinical adherence in relation to skinfold thickness after rivastigmine patch application.
The aim of this study was to examine the association between rivastigmine and NAP 226-90 serum concentration and skinfold thickness and to determine the appropriate skinfold thickness for the use of rivastigmine patch in patients with AD.
Patients with AD who continuously used rivastigmine patches (4.6 mg/24 h, 5 cm2) for more than 6 months were recruited. The serum concentrations of rivastigmine and NAP 226-90 were measured. Skinfold thickness was measured using a Lange Skinfold Caliper.
In total, 91 patients with AD (40 men and 51 women) participated in this study on skinfold thickness measurement. Among them, 27 patients were examined for rivastigmine and NAP 226-90 serum concentrations, with mean concentrations of 1.0 ± 0.6 ng/mL and 3.6 ± 3.6 ng/mL, respectively. The skinfold thickness in the subscapular area was significantly negatively correlated with the NAP 226-90 serum concentration (Spearman’s rank correlation coefficient = − 0.47, P = .01). In addition, patients with AD and a subscapular skinfold thickness of ≥25 mm exhibited a significantly high risk of decreased Mini-Mental Status Examination score and nonadherence to a rivastigmine patch (odds ratio 3.00; 95% confidence interval = 1.076–8.366, P = .03).
Subscapular skinfold thickness was significantly negatively correlated with the NAP 226-90 serum concentration and may be considered an appropriate predictor of response and adherence to clinical application of a rivastigmine patch.
KeywordsAlzheimer’s disease NAP 226-90 Rivastigmine patch Skinfold thickness
This manuscript was edited by Wallace Academic Editing.
This study was supported by grants from Kaohsiung Medical University Hospital (KMUH-9M40) and Kaohsiung Medical University and Changhua Christian Hospital (105-CCH-KMU-011).
Compliance with ethical standards
All procedures were approved by the Institutional Review Boards of Changhua Christian Hospital and Kaohsiung Medical University Hospital. All of the participants or their legal representatives provided written informed consent.
Conflict of interest
The authors declare that they have no conflict of interest.
- American Alliance for Health PE, Recreation, and Dance (1980) AAHPERD lifetime health related physical fitness: test manualGoogle Scholar
- Enz A, Chappuis A, Dattler A (2004) A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry. Biomed Chromatogr 18:160–166CrossRefGoogle Scholar
- Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R (2007) A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease—rivastigmine patch versus capsule. Int J Geriatr Psychiatry 22:456–467CrossRefGoogle Scholar